Iacopo Olivotto

Cardiology and Cardiovascular Medicine · 2000–2023

A researcher in the Science corpus: 11 papers; trusts 1 researcher and is trusted by 2 researchers here, as inferred from the citation graph.

Subfields

• Cardiology and Cardiovascular Medicine — 144 citations into it; #477 of 906 by trust here, #103 by citations

Whom Iacopo Olivotto trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. B. Maron
2. M. Maron

Who trusts Iacopo Olivotto overall

1. B. Maron
2. B. J. Gersh
3. Steve R. Ommen
4. A. Marian

Papers from Iacopo Olivotto's perspective

Ordered by how strongly the researchers Iacopo Olivotto trusts endorse each paper. Same corpus, a different order for every researcher.

1. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. (Journal of the American College of Cardiology)
2. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. (JACC Cardiovascular Imaging)
3. Assessment of Myocardial Fibrosis with Cardiac Magnetic Resonance (Journal of the American College of Cardiology)
4. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. (Journal of the American College of Cardiology)
5. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice… (Journal of Thoracic and Cardiovascular Surgery)
6. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond (Statistics in Medicine)
7. Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors
8. Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives.
9. Myocardial Fibrosis as an Early Manifestation of Hypertrophic Cardiomyopathy (New England Journal of Medicine)
10. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. (New England Journal of Medicine)

Their papers

• 2023 ESC Guidelines for the management of cardiomyopathies. (2023) — 2,144 citations
• Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. (2020) — 881 citations
• Prognostic Value of Quantitative Contrast-Enhanced Cardiovascular Magnetic Resonance for the Evaluation of Sudden Death Risk in Patients With Hypertrophic Cardiomyopathy (2014) — 917 citations
• Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. (2014) — 632 citations
• Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction (2006) — 924 citations
• Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. (2005) — 768 citations
• Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. (2003) — 745 citations
• Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. (2003) — 1,388 citations
• Impact of Atrial Fibrillation on the Clinical Course of Hypertrophic Cardiomyopathy (2001) — 824 citations
• Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. (2000) — 811 citations
• Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. (2000) — 875 citations